Catalio Capital Management operates as a multi-strategy life sciences investment platform built around a formal network of 45+ scientist-entrepreneurs as Venture Partners—including Nobel and Breakthrough Prize winners—who both found companies and provide scientific diligence across all investments, with these partners collectively having founded 170+ companies and receiving equity interests across all Catalio strategies. The firm actively originates new companies from its scientific network at elite institutions like Johns Hopkins and Rockefeller while also investing across the capital structure from inception to IPO, and has distributed nearly $300M to investors since 2020 while most venture funds raised during that period have returned nothing.